Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00450281
Official study title

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Study summary

RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedchromogenic in situ hybridization and gene expression analysis

Plus 9 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 26, 2015 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?405 U.S. locations

Locations may change over time.

Who runs it?SWOG Cancer Research Network

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
SWOG Cancer Research Network
Interventions being studied
Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • DISEASE CHARACTERISTICS:
  • Histologically confirmed non-small cell lung cancer
  • Stage I, II, IIIA, or IIIB (T4 or N3) disease
  • No malignant pleural effusion; if pleural fluid is present, 1 of the following criteria must be met:
  • Benign pleural fluid
  • Pleural fluid is due to prior thoracotomy
  • Pleural fluid is deemed too small to safely tap
  • No diagnosis by cytology alone
  • Newly diagnosed disease
  • Must have tumor blocks/slides available and must be willing to provide tissue samples
  • Prior smoking history meeting 1 of the following criteria:
  • Never smoker, defined as \< 100 cigarettes in lifetime
  • Former smoker, defined as no smoking for ≥ 1 year
  • Current smoker, defined as all others (closed to accrual as of 7/15/07)
  • No pericardial effusions PATIENT CHARACTERISTICS:
  • No other prior malignancy except for 1 of the following:
  • Adequately treated basal cell or squamous cell skin cancer
  • In situ cervical cancer
  • Other cancer for which the patient has been disease free for five years PRIOR CONCURRENT THERAPY:
  • No prior chemotherapy or radiotherapy
  • Concurrent participation in therapeutic trials allowed

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Providence Cancer CenterAnchorage, Alaska
  • Arizona Cancer Center at University of Arizona Health Sciences CenterTucson, Arizona
  • Hembree Mercy Cancer Center at St. Edward Mercy Medical CenterFort Smith, Arkansas
  • Kaiser Permanente - Deer ValleyAntioch, California
  • Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical CenterBurbank, California
  • Cancer Care Center at John Muir Health - Concord CampusConcord, California
  • North Bay Cancer CenterFairfield, California
  • Kaiser Permanente - FremontFremont, California
  • Glendale Memorial Hospital Comprehensive Cancer CenterGlendale, California
  • Kaiser Permanente Medical Center - HaywardHayward, California
  • Tibotec Therapeutics - Division of Ortho Biotech Products, LPMarysville, California
  • Kaiser Permanente Medical Center - OaklandOakland, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 26, 2015. Always confirm current availability with the study team.

View original record ↗